proxyvotesnow.com

Home › Companies › Enliven Therapeutics, Inc. › 2025-2026

Enliven Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

  • 6Reported items
  • 187Asset managers
  • 1,587Fund votes
  • 2026-06-09Meeting date

Proxy season: 2025-2026

Explore Enliven Therapeutics, Inc. in the interactive database Compare manager voting policies

How asset managers voted at the Enliven Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 187 asset managers that disclosed a Enliven Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Enliven Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, in an advisory (non- binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

95% fund support · no official result

FOR 95%

The 186 asset managers below cast 95% of the shares they voted on this item FOR (55,190,069 for, 2,824,477 against).

FOR: 55,190,069 (95.1%)AGAINST: 2,824,477 (4.9%)ABSTAIN: 18,193 (0.0%)
Largest asset managers voting on “To approve, in an advisory (non- binding) vote, the compensation of our named executive officers as disclosed ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity11,443,3690 00For
Polar Capital Holdings Plc9,884,3360 00For
ORBIMED ADVISORS LLC7,957,4130 00For
BlackRock3,130,5625,935 00For
Vanguard2,832,5505,771 00For
Commodore Capital LP2,410,0000 00For
Vestal Point Capital, LP2,356,3330 00For
Fairmount Funds Management LLC1,855,6440 00For
Novo Holdings A/S1,200,0000 00For
Venrock Adviser, LLC1,175,6720 00For
AllianceBernstein1,150,2380 00For
GEODE CAPITAL MANAGEMENT, LLC1,032,5590 00For
Citadel1,010,5290 00For
PICTET ASSET MANAGEMENT SA929,2800 00For
State Street840,6052,157 00For
Rock Springs Capital Management LP808,0950 00For
Siren, L.L.C.746,2260 00For
Charles Schwab728,0730 00For
Candriam S.C.A.0594,079 00Against
Affinity Asset Advisors, LLC418,5190 00For
Avidity Partners Management LP0400,000 00Against
First Light Asset Management, LLC343,5590 00For
Dimensional0297,843 00Against
Northern Trust10,675260,784 00Against
T. Rowe Price251,5500 00For

Showing the 25 largest of 186 asset managers. See all 186 in the interactive database.

2. To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 70%1 YEAR 28%

The 185 asset managers below cast 99.9% of the shares they voted on this item FOR (716,154 for, 194 against).

FOR: 716,154 (1.2%)AGAINST: 194 (0.0%)ABSTAIN: 17,488 (0.0%)ONE YEAR: 40,806,109 (70.2%)1 YEAR: 16,066,985 (27.6%)THREE YEARS: 300,977 (0.5%)1-YEAR: 240,012 (0.4%)3 YEARS: 10,511 (0.0%)1.0: 90 (0.0%)2.0: 3 (0.0%)3.0: 1 (0.0%)
Largest asset managers voting on “To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the comp” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00One Year
Polar Capital Holdings Plc00 00One Year
ORBIMED ADVISORS LLC00 001 Year
BlackRock00 001 Year
Vanguard00 00One Year
Commodore Capital LP00 00One Year
Vestal Point Capital, LP00 00One Year
Fairmount Funds Management LLC00 00One Year
Novo Holdings A/S00 001 Year
Venrock Adviser, LLC00 00One Year
AllianceBernstein00 00One Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Citadel00 00One Year
PICTET ASSET MANAGEMENT SA00 00One Year
State Street00 00One Year
Rock Springs Capital Management LP00 00One Year
Siren, L.L.C.00 001 Year
Charles Schwab00 001 Year
Candriam S.C.A.00 00One Year
Affinity Asset Advisors, LLC00 001 Year
Avidity Partners Management LP00 001 Year
First Light Asset Management, LLC343,5590 00For
Dimensional00 00Three Years
Northern Trust00 001 Year
T. Rowe Price00 00One Year

Showing the 25 largest of 185 asset managers. See all 185 in the interactive database.

3. To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.

CAPITAL STRUCTURE

99.7% fund support · no official result

FOR 99.7%

The 56 asset managers below cast 99.7% of the shares they voted on this item FOR (12,458,194 for, 33,449 against).

FOR: 12,458,194 (99.7%)AGAINST: 33,449 (0.3%)ABSTAIN: 3 (0.0%)
Largest asset managers voting on “To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard2,472,3093,866 30For
BlackRock1,729,1250 00For
AllianceBernstein409,9170 00For
Charles Schwab361,1170 00For
Dimensional227,3200 00For
Prudential/PGIM167,36511,800 00For
Principal92,5470 00For
T. Rowe Price92,0020 00For
Equitable88,3120 00For
State Street81,47330 00For
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century54,4380 00For
Tema ETF Trust49,5890 00For
Lincoln Financial45,5510 00For
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III35,883266 00For
Brighthouse12,50217,488 00Against
Northern Trust24,1600 00For
AIG/SunAmerica20,6850 00For
Global X18,6310 00For
ProShares15,6380 00For
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

4. To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Lori Kunkel, M.D.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 71%ABSTAIN 29%

The 56 asset managers below cast 100% of the shares they voted on this item FOR (8,893,647 for, 0 against).

FOR: 8,893,647 (71.2%)ABSTAIN: 3,597,999 (28.8%)
Largest asset managers voting on “To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard8,9800 2,467,1980Abstain
BlackRock1,729,1250 00For
AllianceBernstein00 409,9170Abstain
Charles Schwab361,1170 00For
Dimensional00 227,3200Abstain
Prudential/PGIM137,4390 41,7260For
Principal00 92,5470Abstain
T. Rowe Price92,0020 00For
Equitable63,4220 24,8900For
State Street800 81,4230Abstain
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century00 54,4380Abstain
Tema ETF Trust49,5890 00For
Lincoln Financial00 45,5510Abstain
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III36,1490 00For
Brighthouse00 29,9900Abstain
Northern Trust00 24,1600Abstain
AIG/SunAmerica00 20,6850Abstain
Global X18,6310 00For
ProShares00 15,6380Abstain
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

5. To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Richard Fair, M.B.A.

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.8%

The 56 asset managers below cast 100% of the shares they voted on this item FOR (12,474,150 for, 0 against).

FOR: 12,474,150 (99.9%)ABSTAIN: 17,497 (0.1%)
Largest asset managers voting on “To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard2,476,1780 00For
BlackRock1,729,1250 00For
AllianceBernstein409,9170 00For
Charles Schwab361,1170 00For
Dimensional227,3200 00For
Prudential/PGIM179,1650 00For
Principal92,5470 00For
T. Rowe Price92,0020 00For
Equitable88,3120 00For
State Street81,4940 90For
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century54,4380 00For
Tema ETF Trust49,5890 00For
Lincoln Financial45,5510 00For
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III36,1490 00For
Brighthouse12,5020 17,4880Abstain
Northern Trust24,1600 00For
AIG/SunAmerica20,6850 00For
Global X18,6310 00For
ProShares15,6380 00For
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

6. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.

AUDIT-RELATED

100% fund support · no official result

FOR 99.8%

The 56 asset managers below cast 100% of the shares they voted on this item FOR (12,474,159 for, 0 against).

FOR: 12,474,159 (99.9%)ABSTAIN: 17,488 (0.1%)
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for ou” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard2,476,1780 00For
BlackRock1,729,1250 00For
AllianceBernstein409,9170 00For
Charles Schwab361,1170 00For
Dimensional227,3200 00For
Prudential/PGIM179,1650 00For
Principal92,5470 00For
T. Rowe Price92,0020 00For
Equitable88,3120 00For
State Street81,5030 00For
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century54,4380 00For
Tema ETF Trust49,5890 00For
Lincoln Financial45,5510 00For
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III36,1490 00For
Brighthouse12,5020 17,4880Abstain
Northern Trust24,1600 00For
AIG/SunAmerica20,6850 00For
Global X18,6310 00For
ProShares15,6380 00For
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Largest Enliven Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Enliven Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 60,889,655 shares outstanding at the time of that meeting.

Top Enliven Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 18.79%
2Polar Capital Holdings Plc 16.23%
3ORBIMED ADVISORS LLC 13.07%
4BlackRock 5.15%
5Vanguard 4.66%
6Commodore Capital LP 3.96%
7Vestal Point Capital, LP 3.87%
8Fairmount Funds Management LLC 3.05%
9Novo Holdings A/S 1.97%
10Venrock Adviser, LLC 1.93%

Reported Enliven Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Enliven Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Entities affiliated with OrbiMed Advisors LLC 13.07% DEF14A
Entities affiliated with FMR LLC 12.93% DEF14A
FMR (Fidelity) 11.22% 13F
Polar Capital Holdings Plc 8.30% 13G
Commodore Capital LP 7.88% 13G
Fairmount Healthcare Fund II LP 6.10% DEF14A
BlackRock 6.05% 13F
Vestal Point Capital, LP 5.34% 13G
Entities affiliated with Venrock Healthcare Capital Partners 5.30% DEF14A
Vanguard Group 4.60% 13F

Percentages above are of 60,889,655 shares outstanding, as reported by Enliven Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Enliven Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Enliven Therapeutics, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 187 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,587 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, in an advisory (non- binding) vote, the compensation of our named executive… — the reporting funds cast 95% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Enliven Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).